SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding (SHIELD)

Keating et al., NCT04478019, SHIELD, NCT04478019, Jun 2022

Chlorhexidine

52nd treatment shown to reduce risk in November 2023, now with p < 0.00000000001 from 5 studies.

Lower risk for progression, cases, and viral clearance.

No treatment is 100% effective. Protocols combine treatments.

6,300+ studies for 210+ treatments. c19early.org

Meta Analysis

245 participant chlorhexidine + PVP-I prophylaxis RCT with results not reported over 3 years after completion.

3 chlorhexidine RCTs have results missing long after expected1-3
The trials report a total of 383 patients, with 2 trials having actual enrollment of 293, and the other estimated.

Important missing comments or errors? Let us know.

Study covers chlorhexidine and povidone-iodine.

1. Keating et al., SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding (SHIELD), NCT04478019, clinicaltrials.gov/study/NCT04478019clinicaltrials.gov.

2. Xie et al., Oral Rinse to Reduced Expelled Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) During COVID-19 Infection, NCT04931004, clinicaltrials.gov/study/NCT04931004clinicaltrials.gov.

3. Mira et al., Evaluation of the Efficacy of Mouth Rinses With Commercial Mouthwashes to Decrease Viral Load in Saliva in COVID-19 Patients, NCT05543603, clinicaltrials.gov/study/NCT05543603clinicaltrials.gov.

Keating et al., 30 Jun 2022, Randomized Controlled Trial, USA, this trial uses multiple treatments in the treatment arm (combined with PVP-I) - results of individual treatments may vary, trial NCT04478019 (history) (SHIELD). Contact: ns2@medicine.wisc.edu, dshirley@medicine.wisc.edu, jakeating@medicine.wisc.edu, SHIELD@medicine.wisc.edu, klhaight@medicine.wisc.edu, jperzynski@medicine.wisc.edu, mzimbric@medicine.wisc.edu.